论文部分内容阅读
目的:评价华蟾素注射液对原发性肝癌患者血清前白蛋白(prealbumin,PA)及血管内皮生长因子(vascular endothelial growth factor,VEGF)水平的影响。方法:90例肝癌患者,随机分成观察组和对照组。两组肝癌患者均采用肝动脉栓塞化疗(transcatheter hepatic arterial chemoembolization,TACE),同时对照组应用西药护肝及增加能量药物,而观察组在对照组用药方式基础上,加用华蟾素注射液治疗。结果:TACE治疗后30 d,观察组总有效率64.44%高于对照组42.22%,差异有统计学意义(P<0.05)。TACE治疗后5 d,两组肝癌患者PA水平均显著低于治疗前,差异有统计学意义(P<0.01)。TACE治疗后30 d,观察组PA水平(2.45±0.75)mmol·L-1高于对照组PA水平(2.14±0.64)mmol·L-1,差异有统计学意义(P<0.05)。TACE治疗后30 d,观察组PA水平与治疗前比较,差异无统计学意义(P>0.05)。TACE治疗后5d、30d,两组VEGF水平均低于治疗前,差异有统计学意义(P<0.01)。TACE治疗后30 d,观察组VEGF水平(167.2±37.2)pg·mL-1低于对照组VEGF水平(246.5±39.5)pg·mL-1,差异有统计学意义(P<0.01)。结论:华蟾素注射液联合TACT术治疗肝癌的疗效可靠,可明显改善患者的预后。华蟾素注射液能有效地提高TACE术后肝癌患者的血清PA水平,促进肝功能恢复。华蟾素注射液能有效抑制TACE术后肝癌患者的血清VEGF水平。
Objective: To evaluate the effect of Huachansu injection on serum prealbumin (PA) and vascular endothelial growth factor (VEGF) levels in patients with primary liver cancer. Methods: Ninety patients with liver cancer were randomly divided into observation group and control group. The two groups of patients with hepatocellular carcinoma were treated with transcatheter hepatic arterial chemoembolization (TACE). Simultaneously, western medicine was used to protect the liver and energy was added to the control group. The observation group was treated with Huachansu injection on the basis of the control group. . Results: 30 days after TACE treatment, the total effective rate of observation group was 64.44% higher than the control group 42.22%, the difference was statistically significant (P<0.05). Five days after TACE treatment, PA levels in patients with liver cancer were significantly lower than those before treatment. The difference was statistically significant (P<0.01). 30 days after TACE treatment, the PA level in the observation group was (2.45±0.75) mmol·L-1 higher than that in the control group (2.14±0.64) mmol·L-1, and the difference was statistically significant (P<0.05). 30 days after TACE treatment, there was no significant difference in PA level between the observation group and pretreatment (P>0.05). At 5 days and 30 days after TACE treatment, the levels of VEGF in both groups were lower than those before treatment, and the difference was statistically significant (P<0.01). 30 days after TACE treatment, the VEGF level in the observation group was (167.2±37.2) pg·mL-1 lower than that in the control group (246.5±39.5) pg·mL-1, and the difference was statistically significant (P<0.01). Conclusion: The efficacy of Huachansu injection combined with TACT in the treatment of liver cancer is reliable and can significantly improve the prognosis of patients. Huachansu injection can effectively increase the serum PA level of liver cancer patients after TACE and promote liver function recovery. Huachansu injection can effectively inhibit serum VEGF levels in patients with hepatocellular carcinoma after TACE.